$GGBXF Industry Growth In Nevada

Point Roberts, WA and Delta, BC – September 9, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot reporting on the Nevada cannabis market and how specifically, Las Vegas is drawing in more consumers and driving more businesses.

In recent sector news it’s been reported that Nevada’s cannabis industry has given more than $100 million in taxes and fees to the state for the first time since recreational marijuana became legal in 2017.

For the fiscal year 2019, dispensaries, cultivators, laboratories and producers have paid over $109 million, according to a September 4, 2019 release from the Nevada Dispensary Association.

NDA says that $99.18 million was paid in taxes, up nearly $25 million from 2018.

“These sales and tax figures are a milestone that should be celebrated by the people of Nevada,” said Riana Durrett of the Dispensary Association. “It shows that the public and visitors to Las Vegas from around the nation are becoming more comfortable purchasing cannabis and the industry is improving its ability to serve the public.”

Las Vegas is also now home to one of the preeminent cannabis conferences, MJBizCon, which is one of the largest gatherings of cannabis business professionals. Ranked as the fastest-growing trade show in the United States, it has grown to over 27,000 attendees since it started in 2012, with an expected 35,000 attendees for the upcoming show taking place December 11-13, 2019 at the Las Vegas Convention Center in Las Vegas.

Global Payout Inc. (OTC: GOHE) and its wholly owned subsidiary MTrac Tech Corporation announced that the Company has expanded its Las Vegas operations office by acquiring office space directly adjacent to the office MTrac has utilized as the hub for its operational team for more than a year.

The significant growth surge the Company has experienced this year onboarding and servicing some of the largest retail and delivery service companies in the cannabis industry has led the Company to strategically add talented new members to its operations support team at a steady, yet effective rate over the last several months. As a result, the Company was thrilled to take advantage of an opportunity that became available to them to acquire additional office space in the adjoining unit to their current office.

“Growth is always an exciting thing to experience as a company,” said Global Payout COO, David Flores. “The core of our team has been intact since we first began our mission of cornering the payment processing sector in the cannabis industry over a year ago, and they have done a phenomenal job managing and contributing to this impressive influx of business. However, as we continue to expand, and as the overall demand for our solution continues to push towards new heights, it is critical that our team is able to successfully meet the needs and demands of a growing client base to ensure that our pledge for exceptional service is never compromised. This expansion provides us with much-needed flexibility to sensibly and efficiently add key members to our operational support staff who are vital in managing the day-to-day responsibilities involved with running our business effectively.”

“The location of the MTrac office is strategic for our headquarters, only a few miles from the airport, adjacent to the Las Vegas strip and in a prime real estate location near the new stadium. Recent renovations were done to the building and MTrac will have a live demo area where clients can come experience the ease of the system in the coming months.”

Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF), a leading vertically-integrated Nevada cannabis company, recently announced that it served an average of 2,027 customers per day in August at an average ticket of $90.25 from the Planet 13 Las Vegas Cannabis Entertainment Complex.

“The highly competitive Las Vegas market ‘The SuperStore’ continues to dominate based on the strength of the customer experience and the unique entertainment it offers,” said Bob Groesbeck, Co-CEO of Planet 13. “Over the rest of the year we will continue to rollout new and exciting restaurants, stores and attractions allowing customers to eat, shop, and play all under one cannabis inspired roof.”

The company also recently reported second-quarter revenues of $16.5 million, up by 275% year-over-year.

Green Growth Brands Inc. (CSE: GGB) (OTC: GGBXF) recently announced the closing of its acquisition of Henderson Organic Remedies, LLC (The+Source Henderson), which was previously disclosed on December 14, 2018. The+Source Henderson is the second The+Source dispensary operated by GGB in greater Las Vegas. The productivity of The+Source Henderson is similar to that of The+Source Las Vegas.

“The+Source Henderson has been under our management for the last nine months,” said Peter Horvath, CEO of Green Growth Brands. “In that time, we have grown revenue, transactions and gross margin by double digits. Our ability to significantly improve top performing dispensaries, in a market that has seen a significant uptick in competition, is a testament to our expertise in retail operations.”

The formal acquisition of the company brings GGB’s Las Vegas assets to two The+Source locations, one production facility, two cultivation facilities and seven licenses to operate dispensaries awarded by the Nevada Department of Taxation.

Green Thumb Industries Inc. (CSE:GTII) (OTC: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise and Essence retail stores, recently reported its financial results for the second quarter ended June 30, 2019.

Second quarter 2019 revenue increased 228% year-over-year to $44.7 million while quarter-over-quarter revenue increased 60%, a record sequential growth for GTI. Revenue growth was driven by organic growth across the Company’s consumer products and retail businesses, strategic acquisitions and increased store traffic.

“We are pleased to report another solid quarter of positive yet disciplined momentum with record revenue and positive adjusted operating EBITDA as our strategic plan delivers on operating efficiencies from scale. Continued execution of key priorities such as the closing of Integral Associates, accelerated store openings, and expanded distribution of our brand portfolio sets us up well for the future,” said GTI Founder and Chief Executive Officer, Ben Kovler.

“We are deep in the chapter of maximizing the levers in our business to drive long-term operational performance that delivers value for our shareholders and the communities in which we operate,” Kovler continued. “We are focused on optimizing our wholesale and retail businesses, integrating our acquisitions, and further strengthening compliance across the organization. We are pleased to see many of these efforts are already bearing fruit as we head into the second half of 2019 and I want to thank our team for all of their hard work.”

On June 5th, GTI successfully completed the acquisition of Integral Associates LLC, with integration efforts and synergies progressing on schedule. The acquisition added two cultivation and processing facilities in Las Vegas, supporting expanded wholesale distribution of GTI’s branded products portfolio in Nevada.

Following the closing of the acquisition of Integral Associates on June 5th, the company’s co-founders Armen and Alex Yemenidijian joined GTI as President and Director, respectively. Armen was the co-founder and CEO of Integral Associates, Nevada’s leading operator and was previously the Chairman of the Board and Chief Executive Officer of Tropicana Las Vegas Hotel & Casino, Inc. and Chairman of the Board and Chief Executive Officer of Metro-Goldwyn-Mayer Inc.

Las Vegas has been well known for its tourism industry and as a greater number of tourists and locals begin to feel more comfortable with the legal cannabis market, and as the market evolves and becomes more efficient, the city and state are creating a huge draw for the cannabis sector. Whether it’s already established MSO’s or celebrity endorsed businesses such as Mike Tyson’s Ranch, Vegas is now starting to bear the fruits of a maturing cannabis industry and many are taking note, just waiting to take a bite.

For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks

About Investorideas.com – News that Inspires Big Investing Ideas

https://www.investorideas.com/About/

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/potcasts_investorideas/

Download our Mobile App for iPhone and Android

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure: this news article featuring GOHE is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

$CNPOF $RIV Begins Trading on the Toronto Stock Exchange

TORONTO, Sept. 9, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to announce that, as of the opening of the markets today, its class A subordinated voting shares will begin trading on the Toronto Stock Exchange (the “TSX“) under the ticker symbol “RIV”. This milestone was achieved within less than one year of Canopy Rivers’ initial go-public transaction. No further action is required by existing shareholders.

“We are proud to join a class of issuers that includes many reputable domestic and international companies,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “We believe that graduating to the TSX will improve awareness about Canopy Rivers and enhance liquidity for our shareholders and other market participants.”

On September 24, 2019, Canopy Rivers will participate in the TSX market open ceremony.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the trading of the Company’s class A subordinated voting shares on the TSX; the benefits of graduating to the TSX; and expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in the timing and process for listing on the TSX; the actual impact of the Company’s TSX listing; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$TGODF $TGOD and Caliper Foods, Positive Results of Pharmacokinetic Study

• Study compared Caliper Foods’ proprietary, patent-pending water-soluble cannabinoid technology, Caliper CBD, with CBD in a carrier oil
• Observed total bioavailability of Caliper water-soluble CBD was 4.5 times greater than CBD in a carrier oil
• Higher cannabinoid absorption was observed for Caliper CBD within 15 minutes compared to the maximum absorption of CBD in oil in 45 minutes.

TORONTO and DENVER, Sept. 9, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, and Caliper Foods (formerly Stillwater Foods), a best-in-class provider of water-soluble cannabinoid products, are pleased to unveil the results of a preliminary human pharmacokinetic (“PK“) study of Caliper CBD, Caliper Foods’ proprietary tasteless and odourless water-soluble powder that can be added to almost any food or beverage.

TGOD intends to commercialize organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products. The Company has already developed novel fast-acting formulations leveraging this technology with its lineup of organic teas, shots, chewables, and ready-to-drink beverages.  In the US, Caliper Foods plans to release Caliper CBD, its own line of precision-dosed CBD dissolvables, this fall.

For this study, half of the participants were administered 30mg of Caliper Foods’ water-soluble CBD powder in 8oz of water while the other half received 30mg of CBD dispersed in MCT oil. Blood samples were drawn at pre-determined times over six hours.  Early data shows that the group that received Caliper CBD demonstrated faster onset within 15 minutes, with higher concentrations achieved at 15 minutes compared to the maximum concentration achieved at 45 min with the CBD in oil formulation, and a 4.5-fold higher observed total bioavailability. The CBD was largely eliminated from the body after about 6 hours for both Caliper CBD and CBD oil subjects, and a more rapid reduction was observed with the Caliper CBD subjects after 45 minutes.

Following this promising initial study, TGOD and Caliper Foods will shortly conduct a confirmatory Clinical Phase 1A PK study that will test the Caliper CBD technology formulated into TGOD’s planned portfolio of products including beverages, teas, Infusers, and capsules. The study will be conducted in collaboration with a leading US academic institution.

“We are delighted with these PK results as they confirm the enhanced bioavailability and consistent absorption rates of our proprietary ingredient technology, which can infuse both CBD and THC. This study confirms that consumers absorb 4.5 times more CBD with Caliper CBD than with CBD in MCT oil,” commented Keith Woelfel, Director of R&D at Caliper Foods.  “Our R&D team is working closely with TGOD on the next phase of the clinical study, which, if it confirms the PK results in additional product forms, will make Caliper Foods’ and TGOD’s product suites highly differentiated in terms of substantiated quality.”

“We are thrilled with the results of this preliminary PK study which demonstrate the consistency and precision of Caliper Foods’ proven proprietary technology which is already available in Colorado and which TGOD will commercialize in Canada. Based on this early data, Caliper CBD provides a higher and faster absorption level when compared with CBD-infused oil, which opens a number of possibilities for both the medical and adult-use markets.  Patients and consumers are increasingly informed and savvy, and we plan to seize on the market demand for organic CBD and THC-infused products backed by data-driven science and clinical evidence,” commented Dr. Rav Kumar, Chief Science Officer of TGOD. “We are enthusiastically awaiting our Clinical Phase 1A PK results in time for Cannabis 2.0 in Canada.”

Caliper Foods’ technology consists of a suite of zero-calorie, fast-acting, water-soluble solutions that can simply and easily infuse cannabinoids into beverages, food, and other consumer goods.  It is formulated to quickly absorb into the bloodstream with a predictable onset and offset, allowing these products to offer a consistent, controlled, and safe experience.  While cannabinoids are naturally fat-soluble and tend to have a bitter taste, Caliper Foods’ ingredient technology eliminates the need for fat molecules to speed absorption or added sugar to mask the bitterness. As a result, it enables healthier, better-tasting products with no additional fat, sugar, or artificial flavours.

TGOD has an exclusive agreement with Caliper Foods to license the Caliper CBD’s ingredient technology, as well as other proprietary beverage and food technologies and formulations related to cannabinoid-infused consumer packaged goods within Canada and distribute to certain international jurisdictions outside of the United States.

About The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

About Caliper Foods

Caliper Foods is a functional foods company specializing in the processing, manufacturing, and distribution of soluble cannabinoid-infused consumer packaged goods and ingredients. The company’s business-to-consumer arm (Caliper Consumer Goods) produces and sells it own line of dissolvable, hemp-derived CBD-infused products. Its initial CBD product, Caliper CBD, will be launching nationwide in the Fall of 2019. The company’s business-to-business arm (Caliper Commercial Ingredients), produces a proprietary suite of application-specific formulations of water-soluble hemp-derived CBD that meet the quality control and documentation needs of experienced CPG experts. The company also has a relationship with Stillwater Brands, maker of some of Colorado’s leading THC- and CBD-infused edibles brands, including Ripple dissolvable cannabinoids, Stillwater Gummy Supplements, and Stillwater Teas & Coffee.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future clinical studies, statements about future product development, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

$OGI Receives Health Canada Approval for 76,000 kg/yr1 Production Capacity

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that effective September 6, 2019 it has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations.

The new cultivation rooms represent approximately 15,000 kg/yr¹ of increased target production capacity. These are the first 17 rooms licensed within the Company’s Phase 4B expansion and now brings the Company’s Moncton facility to annualized licensed capacity to a target of 76,000 kg¹.

The licenses are valid until March 27, 2020 and subject to terms and conditions.

“Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date. Our Phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale,” explains Greg Engel, CEO, Organigram.

As a result of this approval, cannabis plants will be moved into these new rooms on a rolling basis commencing immediately. The Company anticipates harvesting product from these new rooms by the end of November assuming normal cultivation timelines. After drying and other post-harvest processing (including packaging) dried flower from these additional rooms is expected to be available for sale to patients and customers in the Company’s fiscal quarter ending February 29, 2020.

Substantial construction of the entire Phase 4B stage remains on schedule for completion in September 2019 and the Company also anticipates submitting the licensing amendment for the remaining 16 Phase 4B cultivation rooms later this month.

The perimeter of Phase 5 of the Company’s expansion, which will include an edibles and derivative product facility and more extraction capacity, is also planned for this Health Canada licensing submission.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors that could change anticipated timelines for filing of submissions, processing times, capacity utilization, cultivation and in market timelines; including risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. We seek safe harbor.

¹ The forward looking estimate of target production capacity, once fully operational, is based on a number of material factors and assumptions. Please see the Company’s most recent MD&A available on SEDAR at www.sedar.com and EDGAR at www.sec.gov and the disclaimer at the end of this release.

$SRAX Partners with Major CPG Brands to Launch New BIGtoken Feature, BIG Rewards™

LOS ANGELES, Sept. 9, 2019 — SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announces it has entered into new partnerships with major consumer packaged goods (CPG) brands to launch BIG Rewards™, a new feature of SRAX’s consumer-managed data marketplace, BIGtoken. BIG Rewards™ enables marketers to engage BIGtoken’s nearly 16 million users to participate in brand research and exclusive offers, effectively expanding BIGtoken’s commercial capabilities, and solving data problems across the digital marketing and advertising industry.

Through BIG Rewards™, U.S. BIGtoken users will have the ability to earn bonus points for participating in exclusive promotions with specific brands and retailers, and for taking part in brand research. Users can participate by first completing a short survey about a brand, retailer, or product; they can then scan their receipts for related product purchases to earn bonus BIGtoken points. BIG Rewards™ not only provides users with the opportunity to benefit from discounts on their everyday purchases, it also enables users to get paid immediately on those earnings.

“This initiative represents one of many ways we can provide BIGtoken offerings beyond data targeting,” says Kristoffer Nelson, COO of SRAX and co-founder of BIGtoken. “BIG Rewards™ addresses the need for brand research during a time when consumers’ behavior towards brands are in constant flux. BIGtoken is quickly becoming a one-stop shop, enabling brands to utilize the BIG platform for research and build digital media campaigns around deep insights.”

“This commercial expansion will be extremely valuable in the shopper marketing space especially as data regulation continues to grow,” says George Stella, Vice President of SRAX Shopper, SRAX’s shopper marketing vertical. “Increased data regulation will make it challenging for media partners to activate against the current state of data. BIG Rewards™ allows brands to position themselves as advocates for their customers’ privacy. It also enables the brands to create future-proof insights while driving verified purchases of products at their retail locations.”

To download the BIGtoken application, please visit: https://bigtoken.app.link/pressdownload. BIG can also be accessed via the web by visiting my.bigtoken.com.

About SRAX
SRAX, Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com.

About BIGtoken
BIGtoken, built by SRAX (NASDAQ: SRAX), is a consumer data management and distribution system. BIG is the first consumer-managed data marketplace where people can own and earn from their data. Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participating consumers earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform. The system also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences. For more information on BIGtoken, visit www.bigtoken.com.

Safe Harbor Statement
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words or expressions such as “anticipate,” “plan,” “will,” “intend,” “believe” or “expect'” or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to expectations of our ability to increase our revenues, satisfy our obligations as they become due, report profitable operations and other risks and uncertainties, as set forth in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of SRAX and are difficult to predict. SRAX undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:
Kirsten Chapman
LHA Investor Relations
415-433-3777
srax@lhai.com

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$POAI Why Predictive Oncology Inc. (NASDAQ: POAI) Is ‘One to Watch’

$LXRP Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery

NEW YORK, Sept. 06, 2019 — via NetworkNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) announces the availability of a NetworkNewsAudio publication titled, “Innovative Drug-Delivery Systems Benefit Patients and Businesses.”

To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/J4u6k

To read the full editorial, visit: http://nnw.fm/4P2sn

Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be.

Lexaria Bioscience Corp.’s DehydraTECH(TM) may be the most novel form of drug delivery discovered in decades. Fatty acids used in the technology mask the smell and taste of the drug and potentially greatly reduce stomach upset. This allows it to be added to all sorts of foods and drinks — oral delivery — without relying on artificial flavors or loads of sugar to mask a drug. This is useful not just for nicotine but for other pharmaceuticals as well.

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$GNPX NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments

NEW YORK, Sept. 06, 2019 — via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope for Cancer Patients.”

To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/Bqm4W

To read the full editorial, visit: http://nnw.fm/k9gI7

Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer.

Imagined in the 1970s and first carried out in the 1980s, gene therapy is one of the newest frontiers in medicine. The therapy involves the delivery of nucleic acids, the tiny building blocks of life, into human cells. This can rewrite the genetics of cells, removing parts that are causing ill health and strengthening those that fight disease.

A number of companies have emerged with the aim of applying gene therapy to specific diseases. For example, Genprex Inc. (NASDAQ:GNPX) specializes in tackling non-small cell lung cancer through its developmental drug Oncoprex(TM).

About Genprex Inc.

Genprex Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc and LinkedIn at linkedin.com/company/genprex.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$CNPOF $RIV.V Approval to List Class A Subordinated Voting Shares on Toronto Stock Exchange

$LXRP Rolls Out Online Sales of Powdered CBD-Rich Hemp Oil

• Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
• A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
• Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels

Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.

The company’s August 22 announcement (http://nnw.fm/Ql3vI) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$TGODF $TGOD Welcomes New Investors, Provides Update on Aurora Ownership

TORONTO, Sept. 4, 2019

• Improves revenue and margin potential by recovering offtake of TGOD’s premium organic cannabis
• Boosts TGOD’s institutional ownership ahead of potential NASDAQ listing
• Unlocks opportunities for new relationships with third party partners

TORONTO, Sept. 4, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) comments on the recent transaction between Aurora Cannabis (“Aurora”) (TSX:ACB) and a syndicate of Canadian banks.  The block trade was executed on September 3 after market close. A total of 28.8 million shares were exchanged at a negotiated price of $3.00 per unit.  The Edmonton-based company still retains a large number of TGOD warrants equivalent to approximately 5% of the Company’s fully diluted shares.

This transaction significantly improves TGOD’s revenue and gross margin mix due to the repatriation of TGOD’s premium organic cannabis previously earmarked for Aurora under the Investor Rights Agreement (the “Agreement“) between the parties. The Agreement included a revenue sharing model with Aurora which would have lowered TGOD’s average selling price and margins.

“Aurora has been an excellent partner during TGOD’s initial development phase; their investment played an important role in our success. The relationship added significant value across multiple areas of the business, including the initial design and construction of our Canadian facilities,” commented Brian Athaide, CEO of TGOD. ” This is the right next step in the relationship as both companies mature and our respective strategies evolve.  It also improves TGOD’s revenue and margin potential on the sale of our premium organic cannabis,” added Athaide.

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about expectations regarding listing on NASDAQ and registration under the U.S. Exchange Act, statements about future profit margins and revenue, statements about future research, development and innovation by the Company, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

$GNPX Gene Therapy Treatments Offer Hope for Cancer Patients

$GNPX Forward Looking Guidance, Updates on Corporate Activities

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website.

“These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.”

Anticipated milestones and future guidance:

2H 2019

• Establish scalability parameters of new, optimized manufacturing method for lipid nanoparticle delivery system as part of new Genprex research and development program
• Complete protocol for Oncoprex + immunotherapy clinical trial
• Prepare and file IND for Oncoprex + immunotherapy clinical trial
• Determine clinical site selection, expansion strategy and contract with clinical sites for Oncoprex + erlotinib clinical trial

1H 2020

• Complete manufacturing scale-up to support trial site expansion and commercial-scale development
• Complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion
• Contract with new clinical trial sites for Oncoprex + immunotherapy clinical trial
• Begin enrolling patients at new clinical sites for Oncoprex + immunotherapy clinical trial

In addition to the milestone updates, Genprex also unveiled in its updated corporate presentation, an overview of the limitations to current NSCLC treatment and a swimmer plot demonstrating results to date of its Phase I/II clinical trial administering Oncoprex in combination with erlotinib against NSCLC. Genprex also recently launched a new interactive timeline on its website where visitors can follow the company’s success since its inception.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our stated milestones and our ability to advance the clinical development, manufacturing and commercialization of our product candidates, and the effects of Oncoprex on cancer. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include our ability to achieve our stated milestones, the timing and effect of our achieving those milestones, and of other factors, on the clinical development, manufacturing and commercialization of our product candidates, the presence and level of TUSC2’s effect on cancer, the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

$POAI is “One to Watch”

• Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year.
• Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations. The treatment market for thyroid cancer is expected to reach $2.1 billion by 2025.
• Skyline Medical has received its first order for four STREAMWAY machines to be sold to local hospitals in India. The Indian healthcare industry is estimated at more than $100 billion, with the nation’s medical device industry valued at more than $6 billion.
• Helomics signed a collaborative research agreement with Pittsburgh-based molecular imaging company, ChemImage, to expand personalized medicine to prostate cancer diagnosis and treatment.
• TumorGenesis and partner 48Hour Discovery received the Alberta Innovates grant for development of novel cancer treatments.

Predictive Oncology Inc. (NASDAQ: POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$TGODF Receives Health Canada Approval to Start Cultivation in Hamilton

TORONTO, Sept. 3, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that it has obtained approval from Health Canada, under the Cannabis Regulations, to expand operations into its new hybrid greenhouse located in Hamilton, Ontario. The 123,000 square foot state-of-the-art facility will serve to increase TGOD’s premium organic cannabis production as it expands its sales in Canada.

TGOD’s hybrid greenhouse is the fruit of years of research and development. From its cutting-edge climate control systems and water recapture systems to LED lighting, it combines the latest technologies with natural elements such as living soil and natural sunlight.  This organic growing facility has a much better environmental footprint and lower waste than traditional large-scale cannabis growing.

“We are thrilled to start using this purpose-built hybrid greenhouse as we ramp up our production of premium organic cannabis, an underserved segment of the market,” commented Brian Athaide, CEO of TGOD.  “Our team pioneered the concept of growing organic cannabis at scale; this hybrid greenhouse has been artfully designed for organic cultivation, allowing us to reliably produce clean, safe and non irradiated cannabis.”

The new facility is the third phase of TGOD’s Hamilton site, measuring 166,000 square feet with an annual production capacity of 17,500 kgs of premium organic cannabis.  In line with its commitment to sustainability, TGOD aims to have the building LEED certified.

The Company is also seeking an eGMP certification for this facility in order to allow for global exports, as laws and regulations permit.

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future facility construction, statements about future production capacity, statements about the achievement of certain certifications in connection with its facilities, statements about the receipt of any regulatory permits or licences, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.